Pfizer announced results from its Phase III clinical trial, JADE MONO-1, of abrocitinib in moderate to severe atopic dermatitis. The drug met all the co-primary and key secondary endpoints related to skin clearance and itch relief compared to placebo. Abrocitinib is...
ALLENTOWN, Pa., Oct. 14, 2019 /PRNewswire/ — Yourway, the only truly integrated premium courier and clinical packager in the industry, announced its establishment of a new location within the European Union providing storage and distribution services, including...
MILL VALLEY, Calif. and MELBOURNE, Australia, Oct. 14, 2019 /PRNewswire/ — Collaborative Medicinal Development, LLC) (“CMD”), a clinical stage biopharmaceutical company with a portfolio of candidates for treatment of neurological and neuropsychiatric...
Mark Terry for Biospace writes: ReveraGen BioPharma presented topline data from an 18-month treatment of Duchenne muscular dystrophy (DMD) patients with vamorolone, a first-in-class steroidal anti-inflammatory. It is being developed as an alternate to corticosteroids...
Patricia Anacio for ALS Today writes: BrainStorm Cell Therapeutics announced that the Phase 3 clinical trial of its cell therapy candidate NurOwn in 200 amyotrophic lateral sclerosis (ALS) patients is fully enrolled and treatment is underway. The randomized,...
REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with...
Email
Text